What are the side effects and risks of Teclistamab-cqyv?

Teritusumab (Teclistamab-cqyv) is an immunotherapy drug for multiple myeloma . Although its mechanism of action is unique and highly targeted, it is still necessary to be highly vigilant about its potential adverse reactions in clinical use. Because it attacks BCMA-expressing myeloma cells by activating T cells, the process is essentially a highly active immune response, so the accompanying side effects are relatively typical and carry certain risks.

One of the most common side effects is cytokine release syndrome (CRS), which usually occurs within hours to days after administration. CRS manifests as fever, hypotension, dyspnea, chills and other symptoms. Its essence is that the immune system releases a large amount of inflammatory mediators, leading to a systemic inflammatory response. Although most CRS is mild to moderate, severe CRS may also be life-threatening. Therefore, patients need to take medication for the first time in a medical institution with experience in CRS management, and cooperate with specialized monitoring and intervention measures.

Another adverse reaction of concern is immune effector cell-associated neurotoxic syndrome (ICANS), which manifests as confusion, speech impairment, epileptiform seizures and even coma. Neurotoxicity usually occurs after CRS but may occur independently, so monitoring of the nervous system is particularly critical. In addition, ICANS is mostly reversible and can be controlled with appropriate supportive treatment such as glucocorticoids.

In terms of conventional side effects, teritolumab can also cause blood system abnormalities, such as neutropenia, anemia, thrombocytopenia, etc. These reactions may increase the risk of infection or bleeding, and some patients require growth factor stimulation or blood transfusion support. The risk of infection is also a focus of this type of immunotherapy, especially opportunistic infections such as herpes zoster and pneumonia, so preventive anti-infective treatment is more common in clinical practice.

In addition, some patients may also experience non-specific reactions such as fatigue, nausea, diarrhea, loss of appetite or rash during treatment. Although the symptoms are mild, close follow-up is still required. More importantly, the treatment cycle of teritusumab is long, and patients need to face long-term fluctuations in the immune system and impact on the quality of life. Therefore, the systemic condition needs to be regularly assessed during treatment and the dosing plan needs to be adjusted appropriately.

Reference materials:https://www.tecvayli.com/